Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis

Cancer Letters

Volumn 330, Issue 2, 2013, Pages 241-249

  Jia, Li ^a   Waxman, David J ^a  

^a Boston University   (United States)

Author keywords

Angiogenesis; Innate anti tumor immunity; Metronomic chemotherapy; Pigment epithelium derived factor (PEDF); Thrombospondin 1

Indexed keywords

CYCLOPHOSPHAMIDE; PIGMENT EPITHELIUM DERIVED FACTOR; THROMBOSPONDIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL INFILTRATION; CHEMOSENSITIVITY; COLON ADENOCARCINOMA; COLON TUMOR; CONTROLLED STUDY; DRUG RESPONSE; GLIOSARCOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; LUNG METASTASIS; MACROPHAGE; MALE; METASTASIS INHIBITION; METRONOMIC DRUG ADMINISTRATION; MICROVASCULARIZATION; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VASCULARIZATION;

ADMINISTRATION, METRONOMIC; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; CELL MOVEMENT; COLONIC NEOPLASMS; CYCLOPHOSPHAMIDE; EYE PROTEINS; HUMANS; MALE; MICE; MICE, INBRED ICR; NEOPLASM METASTASIS; NERVE GROWTH FACTORS; SERPINS; THROMBOSPONDIN 1;

EID: 84873080485     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.11.055     Document Type: Article

References (55)

1. Weis S.M., Cheresh D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med. 2011, 17:1359-1370.
2. Isenberg J.S., Martin-Manso G., Maxhimer J.B., Roberts D.D. Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat. Rev. Cancer 2009, 9:182-194.
3. Lawler P.R., Lawler J. Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb. Perspect. Med. 2012, 2:a006627.
4. Kaur S., Martin-Manso G., Pendrak M.L., Garfield S.H., Isenberg J.S., Roberts D.D. Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J. Biol. Chem. 2010, 285:38923-38932.
5. Willingham S.B., Volkmer J.P., Gentles A.J., Sahoo D., Dalerba P., Mitra S.S., Wang J., Contreras-Trujillo H., Martin R., Cohen J.D., Lovelace P., Scheeren F.A., Chao M.P., Weiskopf K., Tang C., Volkmer A.K., Naik T.J., Storm T.A., Mosley A.R., Edris B., Schmid S.M., Sun C.K., Chua M.S., Murillo O., Rajendran P., Cha A.C., Chin R.K., Kim D., Adorno M., Raveh T., Tseng D., Jaiswal S., Enger P.O., Steinberg G.K., Li G., So S.K., Majeti R., Harsh G.R., van de Rijn M., Teng N.N., Sunwoo J.B., Alizadeh A.A., Clarke M.F., Weissman I.L. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl. Acad Sci. USA 2012, 109:6662-6667.
6. Greenaway J., Lawler J., Moorehead R., Bornstein P., Lamarre J., Petrik J. Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J. Cell. Physiol. 2007, 210:807-818.
7. Martin-Manso G., Galli S., Ridnour L.A., Tsokos M., Wink D.A., Roberts D.D. Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells. Cancer Res. 2008, 68:7090-7099.
8. Campbell N., Greenaway J., Henkin J., Petrik J. ABT-898 induces tumor regression and prolongs survival in a mouse model of epithelial ovarian cancer. Mol. Cancer Ther. 2011, 10:1876-1885.
9. Greenaway J., Henkin J., Lawler J., Moorehead R., Petrik J. ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol. Cancer Ther. 2009, 8:64-74.
10. Nabors L.B., Fiveash J.B., Markert J.M., Kekan M.S., Gillespie G.Y., Huang Z., Johnson M.J., Meleth S., Kuo H., Gladson C.L., Fathallah-Shaykh H.M. A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Arch. Neurol. 2010, 67:313-319.
11. Lin X.D., Chen S.Q., Qi Y.L., Zhu J.W., Tang Y., Lin J.Y. Overexpression of thrombospondin-1 in stromal myofibroblasts is associated with tumor growth and nodal metastasis in gastric carcinoma. J. Surg. Oncol. 2012, 106:94-100.
12. Firlej V., Mathieu J.R., Gilbert C., Lemonnier L., Nakhle J., Gallou-Kabani C., Guarmit B., Morin A., Prevarskaya N., Delongchamps N.B., Cabon F. Thrombospondin-1 triggers cell migration and development of advanced prostate tumors. Cancer Res. 2011, 71:7649-7658.
13. Nucera C., Porrello A., Antonello Z.A., Mekel M., Nehs M.A., Giordano T.J., Gerald D., Benjamin L.E., Priolo C., Puxeddu E., Finn S., Jarzab B., Hodin R.A., Pontecorvi A., Nose V., Lawler J., Parangi S. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc. Natl. Acad Sci. USA 2010, 107:10649-10654.
14. Filleur S., Nelius T., de Riese W., Kennedy R.C. Characterization of PEDF: a multi-functional serpin family protein. J. Cell. Biochem. 2009, 106:769-775.
15. Manalo K.B., Choong P.F.M., Dass C.R. Pigment epithelium-derived factor as an impending therapeutic agent against vascular epithelial growth factor-driven tumor-angiogenesis. Mol. Carcinog. 2011, 50:67-72.
16. Zaichuk T.A., Shroff E.H., Emmanuel R., Filleur S., Nelius T., Volpert O.V. Nuclear factor of activated T cells balances angiogenesis activation and inhibition. J. Exp. Med. 2004, 199:1513-1522.
17. Elayappan B., Ravinarayannan H., Pasha S.P., Lee K.J., Gurunathan S. PEDF inhibits VEGF- and EPO- induced angiogenesis in retinal endothelial cells through interruption of PI3K/Akt phosphorylation. Angiogenesis 2009, 12:313-324.
18. Guan M., Pang C.P., Yam H.F., Cheung K.F., Liu W.W., Lu Y. Inhibition of glioma invasion by overexpression of pigment epithelium-derived factor. Cancer Gene Ther. 2004, 11:325-332.
19. Cai J., Parr C., Watkins G., Jiang W.G., Boulton M. Decreased pigment epithelium-derived factor expression in human breast cancer progression. Clin. Cancer Res. 2006, 12:3510-3517.
20. Orgaz J.L., Ladhani O., Hoek K.S., Fernandez-Barral A., Mihic D., Aguilera O., Seftor E.A., Bernad A., Rodriguez-Peralto J.L., Hendrix M.J., Volpert O.V., Jimenez B. Loss of pigment epithelium-derived factor enables migration, invasion and metastatic spread of human melanoma. Oncogene 2009, 28:4147-4161.
21. Ladhani O., Sanchez-Martinez C., Orgaz J.L., Jimenez B., Volpert O.V. Pigment epithelium-derived factor blocks tumor extravasation by suppressing amoeboid morphology and mesenchymal proteolysis. Neoplasia 2011, 13:633-642.
22. Halin S., Wikstrom P., Rudolfsson S.H., Stattin P., Doll J.A., Crawford S.E., Bergh A. Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat prostate tumors. Cancer Res. 2004, 64:5664-5671.
23. Uehara H., Miyamoto M., Kato K., Ebihara Y., Kaneko H., Hashimoto H., Murakami Y., Hase R., Takahashi R., Mega S., Shichinohe T., Kawarada Y., Itoh T., Okushiba S., Kondo S., Katoh H. Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res. 2004, 64:3533-3537.
24. Ek E.T., Dass C.R., Contreras K.G., Choong P.F. Pigment epithelium-derived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis. Cancer Gene Ther. 2007, 14:616-626.
25. Fernandez-Garcia N.I., Volpert O.V., Jimenez B. Pigment epithelium-derived factor as a multifunctional antitumor factor. J. Mol. Med. (Berl) 2007, 85:15-22.
26. Halin S., Rudolfsson S.H., Doll J.A., Crawford S.E., Wikstrom P., Bergh A. Pigment epithelium-derived factor stimulates tumor macrophage recruitment and is downregulated by the prostate tumor microenvironment. Neoplasia 2010, 12:336-345.
27. Hanahan D., Bergers G., Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 2000, 105:1045-1047.
28. Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D.J., Bohlen P., Kerbel R.S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 2000, 105:R15-24.
29. Pasquier E., Kavallaris M., Andre N. Metronomic chemotherapy: new rationale for new directions. Nat. Rev. Clin. Oncol. 2010, 7:455-465.
30. Andre N., Padovani L., Verschuur A. Metronomic chemotherapy: back to the future!. Drug News Perspect. 2010, 23:143-151.
31. Sistigu A., Viaud S., Chaput N., Bracci L., Proietti E., Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Sem. Immunopathol. 2011, 33:369-383.
32. Rozados V.R., Mainetti L.E., Rico M.J., Zacarias Fluck M.F., Matar P., Scharovsky O.G. The immune response and the therapeutic effect of metronomic chemotherapy with cyclophosphamide. Oncol. Res. 2010, 18:601-605.
33. Doloff J.C., Waxman D.J. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. Cancer Res. 2012, 72:1103-1115.
34. Bocci G., Francia G., Man S., Lawler J., Kerbel R.S. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc. Natl. Acad Sci. USA 2003, 100:12917-12922.
35. Hamano Y., Sugimoto H., Soubasakos M.A., Kieran M., Olsen B.R., Lawler J., Sudhakar A., Kalluri R. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res. 2004, 64:1570-1574.
36. Ma J., Waxman D.J. Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment. Mol. Cancer Ther. 2007, 6:2879-2890.
37. Damber J.-E., Vallbo C., Albertsson P., Lennernas B., Norrby K. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother. Pharmacol. 2006, 58:354-360.
38. Laquente B., Lacasa C., Ginesta M.M., Casanovas O., Figueras A., Galan M., Ribas I.G., Germa J.R., Capella G., Vinals F. Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. Mol. Cancer Ther. 2008, 7:638-647.
39. Iwamoto H., Torimura T., Nakamura T., Hashimoto O., Inoue K., Kurogi J., Niizeki T., Kuwahara R., Abe M., Koga H., Yano H., Kerbel R.S., Ueno T., Sata M. Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma. Neoplasia 2011, 13:187-197.
40. Jounaidi Y., Chen C.S., Veal G.J., Waxman D.J. Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11. Mol. Cancer Ther. 2006, 5:541-555.
41. Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S., Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000, 60:1878-1886.
42. Jounaidi Y., Waxman D.J. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy. Cancer Res. 2001, 61:4437-4444.
43. Ma J., Waxman D.J. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol. Cancer Ther. 2008, 7:3670-3684.
44. Ma J., Waxman D.J. Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib. Clin. Cancer Res. 2009, 15:578-588.
45. Kazerounian S., Yee K.O., Lawler J. Thrombospondins in cancer. Cell. Mol. Life Sci. 2008, 65:700-712.
46. Yang H., Grossniklaus H.E. Constitutive overexpression of pigment epithelium-derived factor inhibition of ocular melanoma growth and metastasis. Invest. Ophthalmol. Vis. Sci. 2010, 51:28-34.
47. Guan M., Jiang H., Xu C., Xu R., Chen Z., Lu Y. Adenovirus-mediated PEDF expression inhibits prostate cancer cell growth and results in augmented expression of PAI-2. Cancer Biol. Ther. 2007, 6:419-425.
48. Abe R., Shimizu T., Yamagishi S., Shibaki A., Amano S., Inagaki Y., Watanabe H., Sugawara H., Nakamura H., Takeuchi M., Imaizumi T., Shimizu H. Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. Am. J. Pathol. 2004, 164:1225-1232.
49. Campbell N.E., Greenaway J., Henkin J., Moorehead R.A., Petrik J. The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer. Neoplasia 2010, 12:275-283.
50. Willett C.G., Boucher Y., di Tomaso E., Duda D.G., Munn L.L., Tong R.T., Chung D.C., Sahani D.V., Kalva S.P., Kozin S.V., Mino M., Cohen K.S., Scadden D.T., Hartford A.C., Fischman A.J., Clark J.W., Ryan D.P., Zhu A.X., Blaszkowsky L.S., Chen H.X., Shellito P.C., Lauwers G.Y., Jain R.K. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 2004, 10:145-147.
51. Ma J., Chen C.S., Blute T., Waxman D.J. Antiangiogenesis enhances intratumoral drug retention. Cancer Res. 2011, 71:2675-2685.
52. Halama N., Braun M., Kahlert C., Spille A., Quack C., Rahbari N., Koch M., Weitz J., Kloor M., Zoernig I., Schirmacher P., Brand K., Grabe N., Falk C.S. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin. Cancer Res. 2011, 17:678-689.
53. Ma J., Waxman D.J. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol. Cancer Ther. 2008, 7:79-89.
54. Yang J., Chen S., Huang X., Han J., Wang Q., Shi D., Cheng R., Gao G., Yang X. Growth suppression of cervical carcinoma by pigment epithelium-derived factor via anti-angiogenesis. Cancer Biol. Ther. 2010, 9:967-974.
55. Hackl C., Man S., Francia G., Milsom C., Xu P., Kerbel R.S. Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut 2012, 62:259-271.